Demant (BATS-CHIXE:DEMANC) - Stock Price, News & Analysis

DEMANC Stock Overview

Operates as a hearing healthcare and audio technology company in Europe, North America, the Asia Pacific, Asia, and internationally. More details

DEMANC fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	3/6
Past Performance	2/6
Financial Health	3/6
Dividends	0/6

Rewards

Trading at 44.5% below our estimate of its fair value

Earnings are forecast to grow 12.38% per year

Earnings have grown 15.5% per year over the past 5 years

Risk Analysis

Shares are highly illiquid

Has a high level of debt

Demant A/S Competitors

Smith & Nephew

LSE:SN.

UK£8.4b

NIOX Group

AIM:NIOX

UK£253.1m

ConvaTec Group

LSE:CTEC

UK£5.1b

EKF Diagnostics Holdings

AIM:EKF

UK£113.4m

Price History & Performance

Summary of all time highs, changes and price drops for Demant
Historical stock prices
Current Share Price	DKK 268.10
52 Week High	DKK 368.00
52 Week Low	DKK 249.60
Beta	1.02
11 Month Change	1.48%
3 Month Change	3.04%
1 Year Change	3.41%
33 Year Change	-18.63%
5 Year Change	29.96%
Change since IPO	157.05%

Recent updates

Shareholder Returns

	DEMANC	GB Medical Equipment	GB Market
7D	0%	7.7%	-0.4%
1Y	3.4%	-2.1%	5.6%

Return vs Industry: DEMANC exceeded the UK Medical Equipment industry which returned -2.1% over the past year.

Return vs Market: DEMANC underperformed the UK Market which returned 5.6% over the past year.

Price Volatility

Is DEMANC's price volatile compared to industry and market?
DEMANC volatility
DEMANC Average Weekly Movement	n/a
Medical Equipment Industry Average Movement	6.1%
Market Average Movement	4.7%
10% most volatile stocks in GB Market	10.2%
10% least volatile stocks in GB Market	2.6%

Stable Share Price: DEMANC's share price has been volatile over the past 3 months compared to the UK market.

Volatility Over Time: Insufficient data to determine DEMANC's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1904	21,501	Søren Nielsen	www.demant.com

Demant A/S operates as a hearing healthcare and audio technology company in Europe, North America, the Asia Pacific, Asia, and internationally. It operates through two segments: Hearing Healthcare and Communications. The Hearing Healthcare segment is involved in the manufacturing, servicing, and sale of hearing aids, and diagnostic products and services.

Demant A/S Fundamentals Summary

How do Demant's earnings and revenue compare to its market cap?
DEMANC fundamental statistics
Market cap	DKK 57.65b
Earnings (TTM)	DKK 2.54b
Revenue (TTM)	DKK 22.84b

22.7x

P/E Ratio

2.5x

P/S Ratio

Is DEMANC overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
DEMANC income statement (TTM)
Revenue	DKK 22.84b
Cost of Revenue	DKK 5.80b
Gross Profit	DKK 17.04b
Other Expenses	DKK 14.50b
Earnings	DKK 2.54b

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	11.64
Gross Margin	74.61%
Net Profit Margin	11.10%
Debt/Equity Ratio	137.5%

How did DEMANC perform over the long term?

See historical performance and comparison

DEMANC Stock Overview

Rewards

Risk Analysis

Demant A/S Competitors

LSE:SN.

UK£8.4b

AIM:NIOX

UK£253.1m

LSE:CTEC

UK£5.1b

AIM:EKF

UK£113.4m

Price History & Performance

Recent News & Updates

Demant A/S Appoints Anne-Karen Hunt as President of Diagnostics Business Area, Effective 1 November 2024

Demant A/S Announces Board Changes

Demant A/S Updates Earnings Guidance for the Year 2024

Cochlear Limited (ASX:COH) acquired Oticon Medical A/s from Demant A/S (CPSE:DEMANT).

Cochlear Limited (ASX:COH) acquired Oticon Medical A/s from Demant A/S (CPSE:DEMANT).

Less than half of directors are independent

Recent updates

Demant A/S Appoints Anne-Karen Hunt as President of Diagnostics Business Area, Effective 1 November 2024

Demant A/S Announces Board Changes

Demant A/S Updates Earnings Guidance for the Year 2024

Cochlear Limited (ASX:COH) acquired Oticon Medical A/s from Demant A/S (CPSE:DEMANT).

Cochlear Limited (ASX:COH) acquired Oticon Medical A/s from Demant A/S (CPSE:DEMANT).

Less than half of directors are independent

Demant A/S Provides Earnings Guidance for the Year 2024

Investor sentiment improves as stock rises 21%

Anja Madsen Announces Not to Stand for Re-Election to the Board of Directors of Demant A/S

Less than half of directors are independent

Demant A/S to Report Nine Months, 2024 Results on Nov 04, 2024

Less than half of directors are independent

Demant A/S Provides Earnings Guidance for the Year 2023

Less than half of directors are independent

Now 21% undervalued

Demant A/S Announces Executive Changes

Less than half of directors are independent

Investor sentiment improves as stock rises 16%

Less than half of directors are independent

Now 22% undervalued

Less than half of directors are independent

Less than half of directors are independent

Demant A/S to Report Fiscal Year 2022 Results on Feb 07, 2023

Less than half of directors are independent

Demant A/S Revised Earnings Guidance for the Full Year of 2022

Less than half of directors are independent

Investor sentiment deteriorated over the past week

Less than half of directors are independent

Demant A/S Revises Earnings Guidance for the Full Year 2022

Less than half of directors are independent

Less than half of directors are independent

Demant A/S (CPSE:DEMANT) acquired remaining 80% interest in ShengWang for CNY.

Less than half of directors are independent

Demant A/S Appoints Niels Wagner to the Board of Directors

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Less than half of directors are independent

Demant A/S Announces Update on Voluntary Field Corrective Action

Less than half of directors are independent

Demant A/Sreiterated Guidance for the Year 2021

Less than half of directors are independent

Less than half of directors are independent

Demant A/S Updates Earnings Guidance for the Year 2021

Independent Director has left the company

Independent Director has left the company

New 90-day high: kr.263

Full year 2020 earnings released: EPS kr.4.68 (vs kr.6.00 in FY 2019)

Revenue beats expectations

Demant A/S Announces Executive Changes

New 90-day high: kr.237

Demant Launches New Flagship Hearing aids

New 90-day high: kr.235

Demant A/S, Annual General Meeting, Mar 05, 2021

Demant A/S Revises Earnings Guidance for the Second Half of Fiscal Year 2020

Shareholder Returns

Price Volatility

About the Company

Demant A/S Fundamentals Summary

22.7x

2.5x